Causal effect of the gut microbiota on the risk of psychiatric disorders and the mediating role of immunophenotypes

Zhisheng Hong1,2*, Ao He3*, Guanglong Huang1*, Xiaofeng Chen1,4, Xiaoyu Wang1,4, Xiaoyang Li1,2, Hailun Chen1,2, Xinqi Zhao1,2, Ying Xu1,4, Yangheng Xu1,4, Pei Ouyang1, Hai Wang1, Jiapeng Deng1, Pengyu Chen1, Xian Zhang1#, Songtao Qi1#, Yaomin Li1#

1Department of Neurosurgery, Institute of Brain Disease, Nanfang Hospital, Southern Medical University, Guangzhou, China, 510515;
2The Second College of Clinical Medicine, Southern Medical University, Guangzhou, China, 510515;
3Central Laboratory of the Second Affiliated Hospital, Kunming Medical University, Kunming, China, 650000;
4The First College of Clinical Medicine, Southern Medical University, Guangzhou, China, 510515;
#Corresponding authors. Guangzhou Dadao Bei Street 1838#, Guangzhou, China, 510515. Fax: +86 20 61641806. E-mail addresses: lym712@163.com (Y.L.), qisongtaonfyy@126.com (S.Q.), xza@smu.edu.cn (X.Z.).
*These authors contributed equally to this work.
Abstract

Background: Growing evidence indicates a significant correlation between the gut microbiota, immune system, and psychiatric disorders. Nevertheless, the impacts and interactions of the gut microbiota and immunophenotypes on psychiatric disorders remain unclear.

Methods: We utilized a bidirectional Mendelian randomization (MR) study to evaluate the causal associations among the gut microbiota, immunophenotypes, and psychiatric disorders, including attention-deficit/hyperactivity disorder (ADHD), major depressive disorder (MDD), posttraumatic stress disorder (PTSD), schizophrenia (SCZ), and Tourette's syndrome (TS). The primary analysis was conducted using the inverse variance weighted (IVW) method, with several complementary sensitivity analyses being performed to ensure the reliability of the results.

Results: Our study reveals significant causal relationships between immunophenotypes, 15 types of gut microbiota, and various psychiatric disorders. We further sought to ascertain whether immunophenotypes act as intermediaries in the pathway from gut microbiota to psychiatric disorders. In particular, three immunophenotypes were identified that mediate the causal effects of different gut microbiota on ADHD. Additionally, one immunophenotype was detected to mediate the causal effects of gut microbiota on PTSD.

Conclusions: Our study indicates that immunophenotypes partially mediate the pathway from the gut microbiota to psychiatric disorders.

Keywords: Gut microbiota; Immunophenotypes; Psychiatric disorders; Mendelian randomization study; Mediation analysis.
1. Introduction

Psychiatric disorders, a kind of life-threatening and debilitating illness with heterogeneous etiology and complicated pathogenesis, incur a deadweight burden and have become a leading cause of disability worldwide [1]. Humanitarian emergencies, pandemics, and fierce competition have significantly increased the incidence of psychiatric disorders, affecting millions of people worldwide due to psychological stress [2]. Consequently, it is of the utmost importance to determine probable causal risk factors for various psychiatric disorders.

An increasing number of studies have reported that psychiatric disorders often overlap genetically and clinically, suggesting that they all share a similar underlying etiological mechanism [3–5]. Currently, the growing field of immuno-psychiatry acknowledges the pivotal role of the immune system in maintaining homeostasis and fortifying the resilience of central nervous system function [6]. Recent evidence indicates that immune dysregulation is involved in the pathophysiology of various psychiatric disorders [7–9]. Microglia, the brain's macrophages, have been implicated in the pathogenesis of multiple psychiatric disorders, including depression, anxiety, and PTSD, through neuroinflammation [10–12]. Nevertheless, the causal associations between the immunophenotype and psychiatric disorders remain incomplete, unsystematic, and unclear.

Studies in humans and animals have reported microbial shifts associated with increased inflammation and alterations in host metabolism [13,14]. These microbes play a pivotal role in the maturation of the immune response, thereby contributing to homeostasis [15]. The microbiome profoundly influences peripheral immune pathways within the gut-brain communication axis, which regulate responses to neurogenesis [16], neuroinflammation [17], neurological injury [18], and neurodegeneration [19]. In addition, a substantial body of previous observational studies has demonstrated that there are discernible differences in the composition of
the gut microbiota between healthy individuals and those diagnosed with various psychiatric disorders [20]. Nevertheless, the intricate nature of the gut microbiota makes it challenging to achieve a comprehensive and detailed understanding solely through observational studies.

A randomized controlled trial (RCT) is considered the most reliable method for establishing a causal relationship in the context of scientific research. However, the implementation of RCTs can be challenging or even unfeasible due to ethical restrictions. As an alternative, Mendelian randomization is an analytical approach that utilizes single nucleotide polymorphisms (SNPs) as an instrumental variable (IV) to investigate the causal relationship between an exposure or a risk factor and a clinically relevant outcome while minimizing the risk of bias and reverse causation [21]. In this study, we employed a systematic bidirectional two-sample MR design to comprehensively investigate the causal effects among the gut microbiome, immunophenotypes, and various psychiatric disorders. Subsequently, we sought to determine whether immunophenotypes act as mediators in the pathway from the gut microbiota to psychiatric disorders.

2. Methods

2.1 Study Design

This study comprises three principal phases. The initial phase involves an examination of the causal effects of 731 immunophenotypes on a range of major psychiatric disorders. This is followed by an investigation of the causal effects of 207 gut microbiota on psychiatric disorders. Finally, a mediation analysis was conducted to examine the role of immunophenotypes in the relationship between the gut microbiota and psychiatric disorders. Furthermore, a reverse MR analysis was conducted to circumvent the potential effects of reverse causality. The general design of our study is shown in Figure 1.
To determine the unbiased causal effects of exposure on outcomes, MR analysis must satisfy three fundamental assumptions: (I) relevance assumption: genetic variants are strongly correlated with exposures; (II) independence assumption: genetic variants are not associated with any confounding factors of the risk exposure-outcome association; (III) exclusion restriction assumption: genetic variants do not affect the outcome except through their potential impact on the exposure of interest [22,23]. This study followed Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Mendelian Randomization Reporting Guidelines [24].

2.2 Genome-wide Association Study Data Sources

Summary levels of the immunophenotype data were obtained from the latest GWAS [25]. The study analyzed a total of 731 immunophenotypes (3,757 Sardinians), comprising 118 absolute cell counts (AC), 389 median fluorescence intensities (MFI) reflecting surface antigen levels, 32 morphological parameters (MP), and 192 relative cell counts (RC). The GWAS data for the gut microbiome were generated from the Dutch Microbiome Project study, which involved a total of 207 gut microbiota (7,738 European individuals) to evaluate the impact of host genetics on the gut microbiota [26].

The GWAS summary data for ADHD [27], MDD [28], PTSD [29], SCZ [30], and TS [31] were derived from the Psychiatric Genomics Consortium (PGC). All cohorts were case-control studies, and cases met the criteria defined in the International Statistical Classification of Diseases and Related Health Problems-10th Revision (ICD-10) diagnosis code or medication prescription.

All participants were of European ancestry. The original publications contain detailed diagnostic criteria and methods used to recruit participants for these GWASs. There was no significant overlap between the GWAS datasets. The characteristics of the selected GWAS data are listed in Table S1.

2.3 Instrumental Variables Selection
First, SNPs significantly associated with the immunophenotypes (P < 5×10^{-6}) and the
gut microbiota (P < 1×10^{-5}) were selected [32,33]. To guarantee the premise of
independence, IVs were pruned with linkage disequilibrium (LD) r^2 > 0.001 in the
1000 Genomes European data within 10 Mb windows [34]. To compensate for
missing SNPs, those with strong linkage disequilibrium (r^2 > 0.8) were utilized [35].
The proportion of variance in the explained phenotype (R^2) was calculated to indicate
the power of MR studies [36]. The F-statistic of each IV was calculated using the
formula \[\frac{R^2}{(1-R^2)} \times \frac{(N-K-1)}{K}\] [37]. To prevent weak instrument bias from
influencing the results, any IV with an F-statistic less than 10 was removed from
consideration. The summary statistics were harmonized, and any mismatched strands
or palindromic SNPs were removed [38]. Additionally, the summary statistics were
aligned to ensure that each genetic variant was associated with the same effect allele.
The research findings are deemed reliable due to the meticulous selection of IVs.

2.4 Primary Analysis

Two-sample MR analysis was conducted using the multiplicative random effects
inverse variance weighted approach to evaluate the causal effects of the gut
microbiota and immunophenotype on psychiatric disorders [39]. To evaluate the
robustness of the primary estimates, the MR-Egger and Weighted Median methods
were employed to corroborate the IVW results [40,41]. The coherence in the
orientation of the odds ratio (OR) for IVW, MR-Egger, and weighted median was
deemed essential for the robustness of the findings. The false discovery rate (FDR)
was utilized to adjust for multiple tests, and a significant causal relationship was
established using an FDR-adjusted threshold of P < 0.05 [42]. A P-value of less than
0.05, but above the FDR threshold, was considered indicative of a nominal
association.

2.5 Mediation Analysis
Following the bidirectional analysis, the significant causal associations between the gut microbiota or immunophenotype, and psychiatric disorders were included in the two-step mediation analysis. Subsequently, the mediation proportions were calculated according to the following formula: $(\beta_1 \times \beta_2) / \beta$, where $\beta_1$ indicates the impact of the gut microbiota on mediators, $\beta_2$ indicates the impact of mediators on psychiatric disorders, and $\beta$ indicates the total impact of the gut microbiota on psychiatric disorders [43]. Standard errors and confidence intervals (CIs) were calculated using delta methods [44]. Effect estimates are reported as beta values ($\beta$) for the continuous outcome and ORs for the binary outcome.

2.6 Sensitivity Analysis

Cochran’s Q statistic was used to assess the heterogeneity across the individual causal effects [45]. A leave-one-out analysis was conducted to detect outlier instrumental variables [46]. MR-Egger regression and MR pleiotropy residual sum and outlier (MR-PRESSO) analyses were performed to evaluate potential horizontal pleiotropy [47,48]. Outliers identified by the MR-PRESSO outlier test were removed step-by-step to reduce the effect of horizontal pleiotropy, and a corrected casual result was recalculated. Furthermore, the Steiger test was employed to negate the potential bias resulting from reverse causality [49].

2.7 Reverse Analysis

To assess the causal effects of psychiatric disorders on the gut microbiota and immunophenotypes, a backward design was employed, with psychiatric disorders serving as the exposures and the gut microbiota or immunophenotypes serving as the outcomes. SNPs significantly associated with ADHD, MDD, and SCZ at the genome-wide significance level ($P < 5 \times 10^{-8}$) were selected, while a higher cutoff ($P < 1 \times 10^{-5}$) was used for PTSD and TS.
All analyses were conducted using R statistical software version 4.3.1 (accessed on October 18, 2023, https://www.r-project.org/). MR analysis was performed using the R-based packages “TwoSampleMR” (v.0.5.9) [50] and “MR_PRESSO” [51].

3. Results

3.1 Instrumental Variables Selection

After performing clumping and linkage disequilibrium pruning, we identified 10,613 SNPs associated with immunophenotypes and 1,962 SNPs related to the gut microbiota. For the reverse analysis, we selected genetic instruments associated with psychiatric disorders, with SNPs ranging from 26 to 155. All instrumental variables exhibited F-statistics exceeding 10, thereby demonstrating a robust association with exposure phenotypes. Further details on the specific genetic instrumental variables used to infer causal effects are provided in Table S2.

3.2 Causal Effects of Immunophenotypes on Psychiatric Disorders

As shown in Figure 2 and Table S3A, we identified 275 potential causal associations between immunophenotypes and five psychiatric disorders. Multiple tests identified 22 significant causal associations, as shown in Figure 3. The results of the subsequent sensitivity analysis were robust to the causal effect analysis, as shown in Tables S3B and S3C.

We identified 54 potential causal associations between immunophenotypes and ADHD. After adjusting for multiple tests, we investigated five immunophenotypes that contribute causally to the risk of ADHD from the myeloid cell panel, namely, the level of HLA DR on CD33dim HLA DR+ CD11b+ (OR = 1.027, 95% CI 1.019 - 1.035, P = 8.41×10^{-11}), the level of CD33 on CD33dim HLA DR+ CD11b- (OR = 1.017, 95% CI 1.008 - 1.026, P = 2.31×10^{-4}), the level of CD33 on basophils (OR = 1.026, 95% CI 1.012 - 1.040, P = 2.69×10^{-4}), the absolute level of monocytic myeloid-derived suppressor cells (Mo MDSCs) (OR = 1.049, 95% CI 1.022 - 1.077, P = 3.35×10^{-4}),
and the level of CD33 on CD33^{dim} HLA DR^+ (OR = 1.025, 95% CI 1.011 - 1.039, P = 5.78 \times 10^{-4}). Furthermore, the genetic increase in the level of herpes virus entry mediator (HVEM) on effector memory (EM) CD4^+ T cells (OR = 0.965, 95% CI 0.951 - 0.980, P = 4.04 \times 10^{-6}) was potentially related to a decreased risk of ADHD. Conversely, the level of CD38 on IgD^+ CD38^{br} (OR = 0.950, 95% CI 0.927 - 0.973, P = 1.72 \times 10^{-5}) increased the incidence of ADHD. Interestingly, our findings indicate a protective effect of elevated lymphocyte FSC-A parameters (OR = 0.947, 95% CI 0.919 - 0.975, P = 2.74 \times 10^{-4}) on the risk of ADHD from a morphological perspective.

However, in leave-one-out analyses, we found that rs3865444 would significantly drive the causal inference of the level of CD33 on CD33^{dim} HLA DR^+ CD11b^-, while rs190188611 would significantly drive the causal inference of lymphocyte FSC-A parameters, respectively. Consequently, both phenotypes were excluded from subsequent mediation analyses, given the robustness of the conclusions.

We identified 52 potential causal associations between immunophenotypes and MDD. After adjusting for multiple tests, we identified the level of CD4 on resting Tregs (OR = 0.972, 95% CI 0.962 - 0.982, P = 3.66 \times 10^{-8}) as a significant protective factor against the risk of MDD.

We identified 63 potential causal associations between immunophenotypes and PTSD. After adjustment for multiple tests, genetic prediction of two immunophenotypes was associated with a decreased risk of PTSD: the level of CD11c on granulocytes (OR = 0.919, 95% CI 0.884 - 0.954, P = 1.15 \times 10^{-5}) and the level of CD25 on IgD^+ CD24^+ (OR = 0.964, 95% CI 0.944 - 0.984, P = 5.24 \times 10^{-5}). Furthermore, six phenotypes were identified as being associated with an increased risk of PTSD: the relative percentage of CD25^{+} CD8^{br} among T cells (OR = 1.080, 95% CI 1.042 - 1.119, P = 2.55 \times 10^{-5}), the level of HVEM on EM CD8^{br} (OR = 1.050, 95% CI 1.026 - 1.073, P = 2.58 \times 10^{-5}), the relative percentage of IgD^- CD24^- among B cells (OR = 1.040, 95% CI 1.021 - 1.059, P = 2.97 \times 10^{-5}), the myeloid DC SSC-A parameter (OR = 1.063, 95% CI 1.031 - 1.096, P = 9.46 \times 10^{-5}), the relative percentage of basophil among CD33^{dim}
HLA DR<sup>-</sup> CD66b<sup>-</sup> (OR = 1.061, 95% CI 1.029 - 1.094, P = 1.39×10<sup>-4</sup>), and the level of IgD on IgD<sup>+</sup> CD38<sup>br</sup> (OR = 1.055, 95% CI 1.024 - 1.086, P = 3.60×10<sup>-4</sup>). However, in leave-one-out analyses, the causal inference of the myeloid DC SSC-A parameter was significantly driven by rs189299852. Consequently, this phenotype was excluded from subsequent mediation analyses.

We identified 53 potential causal associations between immunophenotype and SCZ. After adjusting for multiple tests, the relative percentage of CD11c<sup>+</sup> monocytes among monocytes (OR = 1.087, 95% CI 1.054 - 1.120, P = 8.90×10<sup>-8</sup>), and the relative percentage of HLA DR<sup>+</sup> CD8<sup>br</sup> among T cells (OR = 1.041, 95% CI 1.020 - 1.062, P = 1.27×10<sup>-4</sup>) were identified as risk factors. Furthermore, the level of CD64 on CD14<sup>+</sup> CD16<sup>+</sup> monocytes (OR = 0.939, 95% CI 0.913 - 0.965, P = 5.74×10<sup>-6</sup>), the relative percentage of CD28<sup>-</sup> DN (CD4<sup>-</sup>CD8<sup>-</sup>) among T cells (OR = 0.962, 95% CI 0.946 - 0.985, P = 5.81×10<sup>-6</sup>), and the level of CD38 on transitional cells (OR = 0.951, 95% CI 0.926 - 0.976, P = 1.99×10<sup>-4</sup>) were identified as protective factors.

We identified 53 potential causal associations between immunophenotype and TS. Nevertheless, following the application of multiple test correction, no immunophenotype was found to be significantly associated with TS.

### 3.3 Causal Effects of the Gut Microbiota on Psychiatric Disorders

As shown in Figure 2 and Table S3D, we identified 66 potential causal associations between the gut microbiota and five psychiatric disorders. Multiple tests identified 14 significant causal associations, as shown in Figure 3. The results of the subsequent sensitivity analysis were robust to the causal effect analysis, as shown in Tables S3E and S3F.

A total of 19 nominal causal effects of the gut microbiota on ADHD were identified. After adjustment for the P-value, the MR analysis indicated that the genetic predictions of *Streptococcus parasanguinis* (OR = 0.964, 95% CI 0.946 - 0.982, P =...
8.49×10^{-5}) and Alistipes indistinctus (OR = 0.948, 95% CI 0.920 - 0.976, P = 3.16×10^{-4}) were associated with a decreased risk of ADHD. Conversely, Ruminococcus bromii (OR = 1.110, 95% CI 1.048 - 1.175, P = 3.90×10^{-4}) and Ruminococcus callidus (OR = 1.063, 95% CI 1.026 - 1.101, P = 7.14×10^{-4}) significantly increased the incidence of ADHD. Furthermore, Bacteroides massiliensis (OR = 1.074, 95% CI 1.032 - 1.118, P = 4.19×10^{-4}) was potentially related to a greater risk of ADHD. Interestingly, an unnamed family from the order Clostridiales (OR = 1.102, 95% CI 1.042 - 1.165, P = 6.91×10^{-4}) was identified as a risk factor for ADHD.

A total of eight nominal causal effects of the gut microbiota on MDD were identified. After adjustment for the P-value, no gut microbiota was found to be significantly associated with MDD.

Thirteen nominal causal effects of the gut microbiota on PTSD were identified. After adjustment for the P-value, S. parasanguinis (OR = 0.904, 95% CI 0.880 - 0.929, P = 4.17×10^{-13}) was found to be significantly associated with a decreased risk of PTSD, similar to that observed for ADHD.

A total of five nominal causal effects of the gut microbiota on SCZ were identified. After adjustment for the P-value, genetic prediction of the family Ruminococcaceae (OR = 0.879, 95% CI 0.832 - 0.928, P = 3.76×10^{-6}) was associated with a decreased risk of SCZ. Notably, R. callidus (OR = 1.040, 95% CI 1.024 - 1.055, P = 6.02×10^{-7}), from the family Ruminococcaceae, was determined to be significantly associated with increased susceptibility to SCZ, similar to that observed for ADHD.

A total of 21 nominal causal effects of the gut microbiota on TS were identified. After adjustment for the P-value, the genetic prediction of four gut microbiota (including two genera and two species) was found to be associated with an increased risk of TS. These included Streptococcus thermophilus (OR = 1.123, 95% CI 1.070 - 1.178, P = 2.25×10^{-6}), Ruminococcaceae bacterium D16 (OR = 1.169, 95% CI 1.064 - 1.285, P = 2.31×10^{-6}).
1.14×10^{-3}), genus *Odoribacter* (OR = 1.440, 95% CI 1.186 - 1.750, P = 2.38×10^{-4}),
and an unnamed genus from the family *Ruminococcaceae* (OR = 1.175, 95% CI 1.083 - 1.276, P = 1.13×10^{-4}). Nevertheless, the genus *Barnesiella* (OR = 0.829, 95% CI 0.761 - 0.902, P = 1.58×10^{-5}), which belongs to the same family (family *Porphyromonadaceae*) as the genus *Odoribacter*, was demonstrated to exert a protective effect against TS.

### 3.4 Mediation Analysis

As shown in Figure 4 and Table S4, the gut microbiota and immunophenotype were found to exert causal effects on psychiatric disorders, with the immunophenotype serving as a partial mediator in the pathway from the gut microbiota to ADHD and PTSD. However, in leave-one-out analyses, the causal inferences of *R. bromii* on the level of CD33 on basophils and the level of CD33 on CD33^{dim} HLA DR^− were significantly driven by rs12041621 and rs1884673. Consequently, these phenotypes were excluded from mediation analysis to prevent the introduction of statistical bias due to the influence of a single SNP.

Significant associations were identified between the genetic prediction of *R. bromii* and a decreased level of HVEM on EM CD4^+ (β = -0.325, 95% CI -0.557 - -0.093, P = 5.95×10^{-3}), mediated 11.04% of the causal effect of *R. bromii* on ADHD. Furthermore, we observed suggestive evidence indicating that an elevated level of *R. callidus* was associated with a significantly greater level of HLA DR on CD33^{dim} HLA DR^+ CD11b^+ (β = 0.246, 95% CI 0.173 - 0.319, P = 5.14×10^{-11}), which mediated 10.60% of the causal effect of *R. callidus* on ADHD. Notably, a potential association was identified between the genetic prediction of *S. parasanguinis* and a decreased level of CD38 on IgD^+ CD38^{br} (β = -0.132, 95% CI -0.211 - -0.054, P = 9.20×10^{-4}), which accounted for 17.48% of the causal effect of *S. parasanguinis* on ADHD. Conversely, the genetic prediction of *S. parasanguinis* was an increase in the level of CD25 on IgD^+ CD24^- (β = 0.145, 95% CI 0.067 - 0.224, P = 3.04×10^{-4}), which contributed to 5.35% of the causal effect of *S. parasanguinis* on PTSD.
3.5 Reverse Analysis

According to the backward analysis, as shown in Tables S5A and S5B, the onset of ADHD significantly decreased the relative abundance of *Coprococcus catus* (β = -0.222, 95% CI -0.311 - -0.133, P = 1.04×10⁻⁶). Furthermore, we sought to ascertain whether the previously identified significant causality exhibited reverse interference. As shown in Tables S5C, S5D and S5E, our findings indicate that reverse causality was not a potential factor in these instances.

3.6 Sensitivity Analysis

The Cochran’s Q test indicated the absence of significant heterogeneity. No evidence of horizontal pleiotropy was identified, as the intercept of MR-Egger did not significantly deviate from zero. Additionally, no potential instrumental outliers were detected at the nominal significance level of 0.05 by MR-PRESSO analysis. The leave-one-out results indicate that no single instrumental variable drove the remaining causal effects. These results serve to confirm the validity of our analysis and demonstrate its robustness in avoiding unintentional errors.

4. Discussion

This study presents, for the first time, multiple novel potential associations between genetically predicted gut microbiota or immunophenotypes and psychiatric disorders using bidirectional MR analysis with mediation analysis. In addition, we identified multiple potential pathways of immunophenotype-mediated causality between the gut microbiota and psychiatric disorders. This provides a new direction for understanding how the gut-brain axis may influence psychiatric disorders.

ADHD is a neurodevelopmental disorder that persists, characterized by inattention, hyperactivity, and impulsivity [52]. The prevalence of ADHD varies across populations and age groups, and a meta-analysis suggested that ADHD affects 5% of children and adolescents and 2.5% of adults worldwide [53]. This study demonstrated
that *R. callidus* is associated with an increased risk of ADHD, which is mediated by elevated expression of HLA DR on the CD33\textsuperscript{dim} HLA DR\textsuperscript{+} CD11b\textsuperscript{+} surface. HLA DR gene region has been implicated in several psychiatric disorders, including schizophrenia, bipolar disorder, and autism spectrum disorders [54]. Nevertheless, current research has been unable to identify a correlation between ADHD and HLA. Further studies are necessary to confirm this hypothesis. Moreover, our findings also indicate that *R. bromii* may increase the risk of ADHD by reducing the expression of HVEM on EM CD4\textsuperscript{+}, which is regarded as a protective factor for ADHD. However, few previous studies have suggested this, which may represent a novel perspective that diverges from the previous belief that *R. bromii* is a probiotic [55]. Notably, HVEM plays a role in the maintenance of T-cell immune homeostasis [56]. This phenomenon may be attributed to the diminished coinhibitory effect of HVEM, which stimulates effector memory T cells to secrete copious quantities of cytokines (e.g., IL-17 and IFN-\(\gamma\)) [57,58]. These cytokines trigger neuroinflammation, a process that could contribute to the etiology of ADHD.

This study demonstrated that elevated levels of various myeloid cell phenotypes, particularly high surface expression of CD33, are significantly and positively associated with the risk of developing ADHD. CD33 is a molecule of the Siglec family that is mainly expressed in myeloid cells, including macrophages and dendritic cells, and is involved in regulating cellular activation, differentiation, and inflammatory responses [59]. In addition, microglia, a vital subset of immune cells within the central nervous system, also express CD33 molecules [60]. Synaptic pruning mediated by microglia involves the elimination of excessive or weak synaptic connections, thereby strengthening the more important and efficient neural pathways, which, if their activities are abnormal, can affect neural circuitry development, leading to ADHD-related symptoms [61,62]. Furthermore, under conditions of focal brain injury or neuroinflammation, Mo MDSCs can infiltrate the brain and inhibit neuronal inflammation by suppressing microglia activation, which is triggered by factors like IFN-\(\gamma\), GM-CSF, and TNF [63,64].
Surprisingly, this study revealed that ADHD could decrease the abundance of *C. catus*. Previous studies have shown that the Mediterranean diet can increase the abundance of *C. catus* [65]. It was postulated that patients with ADHD may experience appetite suppression as a side effect of medication or as a consequence of abnormal eating habits resulting from mood changes associated with the onset of ADHD. Consequently, this could result in a reduction in the abundance of *C. catus*. Furthermore, a reduction in the abundance of *C. catus* may result in a decrease in butyrate production, which plays an important anti-inflammatory role in the central nervous system [66,67]. This, in turn, may exacerbate ADHD symptoms. Consequently, fluctuations in the prevalence of *C. catus* can be employed to inform timely modification of the dietary regimen of ADHD patients, thereby preventing exacerbation of the disease by establishing a diverse and healthy gut microbiota.

PTSD is a debilitating mental disorder with a lifetime prevalence of nearly 8% in the general population [68]. Those with PTSD experience a constant state of hyperarousal and fear, which may be associated with abnormal gene expression in the brain and peripheral blood cells [69]. Furthermore, the coaggregation of PTSD and ADHD within families implies the presence of shared familial risk factors for these disorders [70]. In this investigation, *S. parasanguinis* was identified as a co-protective element against ADHD and PTSD. This effect was found to be mediated by CD38 on IgD+ CD38hi and CD25 on IgD+ CD24+. *S. parasanguinis* is a gram-positive coccus that typically forms a symbiotic relationship with the human body and has the capacity to suppress the growth of pathogenic bacteria through the secretion of antibacterial substances [71,72]. Notably, *S. parasanguinis* is known to colonize the gastrointestinal tract and stimulate gene expression in Tregs, resulting in the enhancement of anti-inflammatory cytokine secretion, thus indicating its immunomodulatory capabilities [73]. Given the established associations between ADHD and oxidative stress, as well as neuroinflammation, it can be postulated that *S. parasanguinis* might exert an immunosuppressive effect through the downregulation of CD38, which may play a role in promoting neurodegeneration and inflammatory
harm [74,75]. Equally significant is the role of CD25 in suppressing the activation of self-reactive T cells through mechanisms that are independent of cytokines and reliant on cell contact to promote immune tolerance [76,77]. *S. parasanguinis* has the potential to alleviate chronic low-grade inflammation induced by prolonged stress through the upregulation of CD25, which may contribute to immune regulation, thereby exerting a protective effect on PTSD. Furthermore, the immunophenotypes closely linked to the development of PTSD predominantly consist of B lymphocytes. These cells may enter the prefrontal cortex, insula, amygdala, hippocampus, and other brain regions either by crossing the blood-brain barrier due to the peripheral release of proinflammatory cytokines or by directly infiltrating the central nervous system [78]. This process can intensify the manifestations of fear and anxiety. Further investigation is required to elucidate the potential mechanisms of targeted B-cell intervention for the alleviation or management of PTSD.

SCZ is a severe mental illness characterized by positive symptoms and cognitive impairment [79]. Growing evidence indicates that the gut microbiota may influence social behavior, emotion, and cognition via the gut-brain axis, with the potential to impact the development of SCZ [80]. Our findings suggest that the increased abundance of *Ruminococcus* may be a protective factor for SCZ. *Ruminococcus* species are believed to produce butyrate, which can enhance antioxidant capacity and regulate inflammatory mediators. Surprisingly, we also found that the increased abundance of *R. callidus* may be a risk factor for SCZ, similar to that observed in ADHD patients. Furthermore, our study demonstrated a significant correlation between reduced levels of CD38 in transitional cells and increased susceptibility to SCZ. This finding is substantiated by animal experiments, which underscore the crucial involvement of CD38 in neurodevelopmental mechanisms such as neuropeptide release and social cognition [81]. Moreover, immunophenotypes that include CD8 molecules may increase susceptibility to SCZ, resembling MDD, which is characterized by a reduced CD4/CD8 ratio in acute psychosis episodes [82]. The underlying mechanism remains ambiguous, with speculation suggesting a potential
association with systemic inflammation triggered by adaptive immunity. In addition, various subtypes of monocytes, including the relative percentage of CD11c+ monocytes among monocytes and the level of CD64 on CD14+ CD16+ monocytes, have been shown to exhibit both detrimental and beneficial effects on SCZ. This duality in effects may be attributed to the heterogeneity of monocytes circulating in vivo, which display a combination of proinflammatory and anti-inflammatory traits [83].

MDD is a pervasive mental disorder characterized by persistent low mood, sleep disturbances, cognitive decline, and other symptoms [84]. There is a plethora of evidence indicating that neuroinflammation can precipitate cellular immune disorders and increase the risk of psychiatric disorders, and that Tregs play a pivotal role in regulating the immune response [85]. MDD typically involves stress activation by the immune system, leading to the release of stressor-induced circulating proinflammatory cytokines [86,87]. Consequently, CD4+CD25+ Tregs with immunomodulatory functions may significantly reduce anxiety-like behaviors by inhibiting proinflammatory cytokines such as Th1, Th2, and Th17 cells, thereby alleviating MDD [88]. Importantly, a significant increase in Tregs was previously observed during antidepressant treatment [89], which strongly supports our conclusion. In light of the aforementioned studies, we hypothesized that the level of CD4 on resting Tregs subsets plays an important protective role in the pathogenesis of MDD by regulating neuroinflammation and reducing oxidative stress.

TS is a neurological disorder characterized by repetitive and involuntary movements and vocalizations, and can be divided into motor tics and vocal tics. These symptoms often begin in childhood. A significant body of research has demonstrated that the gut-brain axis plays a pivotal role in the pathophysiology of TS [90]. Fecal microbiota transplantation (FMT) has been identified as a potential treatment for various neurological and psychiatric disorders, including TS, by regulating the microbiota ecology to maintain cytokine balance in the gut lymphoid tissue and reduce the
release of proinflammatory factors [91]. *S. thermophilus* is a safe probiotic with anti-inflammatory, anti-cancer, and antioxidant properties [92]. However, our results showed that a high abundance of *S. thermophilus* was a risk factor for TS, in contrast to previous studies. Given the paucity of studies investigating the relationship between *S. thermophilus* and TS, further research on its mechanism is warranted. In addition, our study demonstrated that the increased abundance of *R. noname*, *G. odoribacter*, and *R. bacterium D16* may be risk factors for TS. This may be because *R. noname* and *R. bacterium D16* both belong to the *Ruminococcaceae* family, and the variation in *R. UCG-004* is positively correlated with the anxiety-like behavior of individuals with ADHD. Importantly, the comorbidity rate of ADHD and TS was 50%, which led us to infer that *G. odoribacter* and *R. bacterium D16* may be common risk factors for both [93,94]. In fact, according to a study by Wang et al., *G. odoribacter* may interfere with the dopamine metabolic pathway to cause TS pathogenesis, which is consistent with our conclusion [95]. Finally, we found that increased abundance of *G. barnesiella* reduced the risk of TS, possibly because *G. barnesiella* is a natural gut microbe involved in competitive inhibition of pathogenic bacteria and immune regulation, improving cognitive function and thereby ameliorating TS-related symptoms [96,97].

There are several limitations to consider in this study. The current GWAS database constraints hinder the analysis of data from other ethnic groups, and caution is advised when interpreting our results in different populations. Moreover, given the inherent diversity among patients with psychiatric disorders, future research could delve into these subgroups in more detail. Finally, further prospective controlled trials may be necessary to investigate the mechanisms underlying the potential roles of recently discovered gut microbiota and immunophenotypes in psychiatric disorders.
5. Conclusion

In summary, our study comprehensively assessed the significant causal relationships between 22 immunophenotypes, 15 gut microbiota, and five psychiatric disorders. Furthermore, four potential causal pathways between gut microbiota, immunophenotypes, and psychiatric disorders were identified. This highlights the intricate pattern of interactions between the gut microbiota, immune system, and psychiatric disorders. These findings provide valuable insights for risk assessment and potential treatment strategies. Consequently, a more comprehensive understanding of the underlying mechanisms governing these causal relationships could facilitate the early identification, intervention, and prevention of psychiatric disorders.

List of abbreviations

MR: Mendelian randomization
ADHD: Attention-deficit/hyperactivity disorder
MDD: Major depressive disorder
PTSD: Posttraumatic stress disorder
SCZ: Schizophrenia
TS: Tourette's syndrome
IVW: Inverse variance weighted
RCT: Randomized controlled trial
SNP: Single nucleotide polymorphism
IV: Instrumental variable
GWAS: Genome-wide association studies

LD: Linkage disequilibrium

OR: Odds ratio

FDR: False discovery rate

CI: Confidence intervals

MR-PRESSO: MR pleiotropy residual sum and outlier analysis

MDSC: myeloid-derived suppressor cells

HVEM: Herpes virus entry mediator

Supplementary Information

Additional file 1: Supplementary Tables.xlsx.

Additional file 2: STROBE-MR checklist.docx.

Acknowledgement

The authors would like to express their gratitude to the investigators of the original studies for sharing the GWAS summary statistics.

Declarations

Competing interests

The authors declare that they have no competing interests.

Ethics approval and consent to participate
All data used in this work are publicly available from studies with relevant participant consent and ethical approval.

Consent for publication

Not applicable.

Authors’ contributions

Z.H., A.H., and G.H. conceived and designed the project. Z.H., and A.H. drafted the manuscript. X.C., X.W., X.L., H.C., and X.Z. investigated and collected the data. Z.H., Y.X.1, Y.X.2, and P.O. supervised and analyzed the data. A.H., G.H., and H.W. conducted validation. J.D., and P.C. visualized the results. Y.L., S.Q., and X.Z. revised the manuscript. All authors carefully revised the manuscript and approved the version submitted.

Funding

This study was supported by the National Natural Science Foundation of China (grant nos. 82203368); President Foundation of Nanfang Hospital, Southern Medical University (2023H020); Science and Technology Projects in Guangzhou (grant nos. 202201011008); Natural Science Foundation of Guangdong Province, China (2023A1515011775); College students' innovative entrepreneurial training plan program (S202212121090); College students' innovative entrepreneurial training plan program (S202312121119).

Data availability

The datasets analyzed in this study are publicly available summary statistics. The data can be obtained through cited papers and websites.

Code availability
All R scripts applied in this study are available from the authors upon reasonable request.

References


11. Smith KL, Kassem MS, Clarke DJ, Kuligowski MP, Bedoya-Pérez MA, Todd SM, et al. Microglial cell hyper-ramification and neuronal dendritic spine loss in the hippocampus and

https://doi.org/10.1016/j.bbi.2019.05.042.

Dynamic microglial alterations underlie stress-induced depressive-like behavior and
https://doi.org/10.1038/mp.2013.155.

modulate the T helper 17 to regulatory T cell (Th17/Treg) imbalance promoting resilience to


https://doi.org/10.1038/sj.embor.7400731.

Traverses the Placenta to Induce Fetal Neuroproliferation and Aberrant Postnatal Behavior.

[17] Rea K, Dinan TG, Cryan JF. The microbiome: A key regulator of stress and
https://doi.org/10.1016/j.jynstr.2016.03.001.

[18] Lee YK, Menezes JS, Umesaki Y, Mazmanian SK. Proinflammatory T-cell responses to gut
microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci

microbiota-dependent progression of neurodegeneration in a mouse model of tauopathy.

Microbiota Composition in Psychiatric Disorders: A Review and Meta-analysis. JAMA

https://doi.org/10.1681/ASN.2016010098.


[23] Larsson SC, Butterworth AS, Burgess S. Mendelian randomization for cardiovascular
https://doi.org/10.1093/eurheartj/ehad736.

al. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian

https://doi.org/10.1038/s41588-020-0684-4.


[54] Tamouza R, Krishnamoorthy R, Leboyer M. Understanding the genetic contribution of the human leukocyte antigen system to common major psychiatric disorders in a world


Antshel KM, Kaul P, Biederman J, Spencer TJ, Hier BO, Hendricks K, et al. Posttraumatic Stress Disorder in Adult Attention-Deficit/Hyperactivity Disorder: Clinical Features and


Figures

Figure 1 The general design of the study.
Figure 2 Volcano plots showing the effect estimates for each exposure to psychiatric disorders. A-E demonstrate the causal effect of immunophenotypes on psychiatric disorders. F-J demonstrate the causal effect of the gut microbiota on psychiatric disorders.
**Figure 3** Mendelian randomization results of causal effects between immunophenotypes, the gut microbiota, and psychiatric disorders.

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Exposures</th>
<th>Panel</th>
<th>IVs</th>
<th>Estimate</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMD</td>
<td>HLA DR on CD38/CD14+ HLA DR+ CD11b+ Myeloid cell</td>
<td>12</td>
<td>1.627 (0.109 - 10.35)</td>
<td>6.15E-08</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HVEM on EM CD8+ Maturation stages of T cell</td>
<td>5</td>
<td>0.965 (0.951 - 0.98)</td>
<td>1.48E-03</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CD38 on IgG+ CD38br</td>
<td>B cell</td>
<td>5</td>
<td>1.050 (1.023 - 1.07)</td>
<td>4.19E-03</td>
</tr>
<tr>
<td></td>
<td>CD33 on CD36, HLA DR+ CD11b+ Myeloid cell</td>
<td>13</td>
<td>1.614 (1.008 - 2.60)</td>
<td>2.33E-02</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CD33 on basel</td>
<td>Myeloid cell</td>
<td>10</td>
<td>1.659 (1.002 - 3.06)</td>
<td>8.31E-02</td>
</tr>
<tr>
<td></td>
<td>FSC A on lymphocyte</td>
<td>TBNK</td>
<td>7</td>
<td>0.947 (0.909 - 0.975)</td>
<td>3.33E-02</td>
</tr>
<tr>
<td></td>
<td>Ma-MDSC AC</td>
<td>Myeloid cell</td>
<td>9</td>
<td>1.649 (1.022 - 1.07)</td>
<td>3.50E-02</td>
</tr>
<tr>
<td></td>
<td>CD38 on CD56, HLA DR-</td>
<td>Myeloid cell</td>
<td>11</td>
<td>1.625 (1.031 - 1.10)</td>
<td>4.71E-02</td>
</tr>
<tr>
<td></td>
<td>CD4 on co-stimulation</td>
<td>Treg</td>
<td>7</td>
<td>0.972 (0.962 - 0.982)</td>
<td>5.65E-05</td>
</tr>
<tr>
<td>PTSD</td>
<td>CD11c on granulocyte</td>
<td>cDC</td>
<td>14</td>
<td>0.919 (0.888 - 0.954)</td>
<td>5.38E-05</td>
</tr>
<tr>
<td></td>
<td>CD25+/ICOS+ % T cell</td>
<td>Treg</td>
<td>10</td>
<td>1.080 (1.042 - 1.11)</td>
<td>5.38E-03</td>
</tr>
<tr>
<td></td>
<td>HVEM on EM CD8+ Maturation stages of T cell</td>
<td>7</td>
<td>1.659 (1.026 - 2.73)</td>
<td>5.38E-03</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IgG+CD24+ % B cell</td>
<td>B cell</td>
<td>12</td>
<td>1.640 (1.021 - 2.05)</td>
<td>5.38E-03</td>
</tr>
<tr>
<td></td>
<td>SS-C- on myeloid DC</td>
<td>cDC</td>
<td>10</td>
<td>1.65 (1.011 - 2.09)</td>
<td>3.77E-02</td>
</tr>
<tr>
<td></td>
<td>Bcaoph %CD38, HLA DR+ CD66b+ Myeloid cell</td>
<td>12</td>
<td>1.630 (1.029 - 1.10)</td>
<td>1.63E-02</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IgG+IgD-CD20+ B cell</td>
<td>B cell</td>
<td>15</td>
<td>1.655 (1.024 - 1.09)</td>
<td>3.78E-02</td>
</tr>
<tr>
<td></td>
<td>CD25 on IgG-CD24</td>
<td>B cell</td>
<td>17</td>
<td>0.964 (0.944 - 0.984)</td>
<td>4.74E-02</td>
</tr>
<tr>
<td>SCZ</td>
<td>CD11c / monocyte</td>
<td>Monocyte</td>
<td>cDC</td>
<td>11</td>
<td>1.087 (1.054 - 1.12)</td>
</tr>
<tr>
<td></td>
<td>CD84 on CD14 / CD16 / monocyte</td>
<td>Monocyte</td>
<td>7</td>
<td>0.939 (0.913 - 0.965)</td>
<td>1.40E-03</td>
</tr>
<tr>
<td></td>
<td>CD25- DN (CD4+CD8+) % T cell</td>
<td>Treg</td>
<td>14</td>
<td>0.962 (0.946 - 0.985)</td>
<td>1.40E-03</td>
</tr>
<tr>
<td></td>
<td>HLA DR+CD8+ % T cell</td>
<td>TBNK</td>
<td>23</td>
<td>1.641 (1.020 - 1.06)</td>
<td>2.85E-02</td>
</tr>
<tr>
<td></td>
<td>CD8 on transitional</td>
<td>B cell</td>
<td>16</td>
<td>0.951 (0.926 - 0.976)</td>
<td>2.85E-02</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Exposures</th>
<th>Family</th>
<th>IVs</th>
<th>Estimate</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMD</td>
<td>S. pneumoniae</td>
<td>Streptococcaceae</td>
<td>3</td>
<td>0.966 (0.936 - 0.992)</td>
<td>1.68E-02</td>
</tr>
<tr>
<td></td>
<td>A. actinomycetemcomitans</td>
<td>Bacteroidaceae</td>
<td>10</td>
<td>0.948 (0.920 - 0.976)</td>
<td>2.97E-02</td>
</tr>
<tr>
<td></td>
<td>R. spheroides</td>
<td>Ruminococcaceae</td>
<td>6</td>
<td>1.110 (1.038 - 1.17)</td>
<td>2.97E-02</td>
</tr>
<tr>
<td>family</td>
<td>C. rectum</td>
<td>Ruminococcaceae</td>
<td>4</td>
<td>1.074 (1.032 - 1.11)</td>
<td>2.97E-02</td>
</tr>
<tr>
<td></td>
<td>C. ruminococcaceae</td>
<td>Clostridiales, bovine</td>
<td>7</td>
<td>1.102 (1.032 - 1.16)</td>
<td>2.56E-03</td>
</tr>
<tr>
<td></td>
<td>R. albus</td>
<td>Ruminococcaceae</td>
<td>5</td>
<td>1.605 (1.056 - 1.95)</td>
<td>3.74E-02</td>
</tr>
<tr>
<td>PSSD</td>
<td>S. pneumoniae</td>
<td>Streptococcaceae</td>
<td>3</td>
<td>0.958 (0.938 - 0.982)</td>
<td>2.17E-11</td>
</tr>
<tr>
<td>SCZ</td>
<td>R. albus</td>
<td>Ruminococcaceae</td>
<td>5</td>
<td>1.640 (1.024 - 1.65)</td>
<td>2.17E-04</td>
</tr>
<tr>
<td>family</td>
<td>Ruminococcaceae</td>
<td>Ruminococcaceae</td>
<td>6</td>
<td>0.878 (0.832 - 0.928)</td>
<td>3.78E-04</td>
</tr>
<tr>
<td>TS</td>
<td>S. thermophiles</td>
<td>Streptococcaceae</td>
<td>4</td>
<td>1.122 (1.070 - 1.17)</td>
<td>2.24E-04</td>
</tr>
<tr>
<td>genus</td>
<td>B. bronchiseptica</td>
<td>Porphyromonadaceae</td>
<td>13</td>
<td>0.859 (0.817 - 0.902)</td>
<td>1.65E-03</td>
</tr>
<tr>
<td>genus</td>
<td>Bacteroidaceae</td>
<td>Ruminococcaceae</td>
<td>8</td>
<td>1.175 (1.083 - 1.27)</td>
<td>5.63E-03</td>
</tr>
<tr>
<td>genus</td>
<td>Clostridiales</td>
<td>Porphyromonadaceae</td>
<td>8</td>
<td>0.140 (1.386 - 1.75)</td>
<td>5.43E-03</td>
</tr>
<tr>
<td>R. albus</td>
<td>Ruminococcaceae</td>
<td>7</td>
<td>1.169 (1.064 - 1.285)</td>
<td>3.71E-02</td>
<td></td>
</tr>
</tbody>
</table>
Figure 4 Immunophenotypes mediate the causal pathways from the gut microbiota to ADHD and PTSD.
Three fundamental assumptions:

1. Relevance assumption: The instrumental variables are strongly associated with the exposure;
2. Independence assumption: The instrumental variables are not associated with any confounding factors of the risk association;
3. Exclusion restriction assumption: The instrumental variables do not affect the outcome except through their potential impact on the exposure of interest.

Primary analysis
- Main analysis
  - IVW
  - MR-Egger
  - Weighted Median
  - Simple mode
  - Weighted mode
- Sensitivity analysis
  - Cochran’s Q test
  - MR-Egger regression test
  - MR-PRESSO
  - leave-one-out analysis
  - Steiger Direction test
  - Reverse analysis

Data Sources
- Lopera-Mayo et al., 2022
- Orrù et al., 2020
- Psychiatric Genomics Consortium
- Demontis et al., 2023
- Howard et al., 2019
- Nievergelt et al., 2019
- Trubetskoy et al., 2022
- Yu et al., 2019

Instrumental Variables
- P-value < 1 × 10⁻⁵
clump-kb 10 Mb
clump-r² 0.001

Two-step analysis
Step 1: MR analysis between Immunophenotypes and Psychiatric Disorders.
Step 2: MR analysis between Gut Microbiota and Psychiatric Disorders.
Step 3: MR analysis between Identified Gut Microbiota and Immunophenotypes

Instrumental Variables
- P-value < 5 × 10⁻⁶
clump-kb 10 Mb
clump-r² 0.001

Instrumental Variables
- P-value < 1 × 10⁻⁵/5 × 10⁻⁸
clump-kb 10 Mb
clump-r² 0.001

Data Sources
- Lopera-Mayo et al., 2022
- 731 Immunophenotypes
  - 190 B cells
  - 64 cDCs
  - 79 Maturation stages of T cell
  - 43 Monocyte
  - 6 Myeloid
  - 124 TBNK
  - 167 Tregs

Data Sources
- Psychiatric Genomics Consortium
  - ADHD Demontis et al., 2023
  - MDD Howard et al., 2019
  - PTSD Nievergelt et al., 2019
  - SCZ Trubetskoy et al., 2022
  - TS Yu et al., 2019

Main analysis
Sensitivity analysis
- Cochran’s Q test
- MR-Egger regression test
- MR-PRESSO
- leave-one-out analysis
- Steiger Direction test
- Reverse analysis

Sensitivity analysis
- Cochran’s Q test
- MR-Egger regression test
- MR-PRESSO
- leave-one-out analysis
- Steiger Direction test
- Reverse analysis

Sensitivity analysis
- Cochran’s Q test
- MR-Egger regression test
- MR-PRESSO
- leave-one-out analysis
- Steiger Direction test
- Reverse analysis

Sensitivity analysis
- Cochran’s Q test
- MR-Egger regression test
- MR-PRESSO
- leave-one-out analysis
- Steiger Direction test
- Reverse analysis

Sensitivity analysis
- Cochran’s Q test
- MR-Egger regression test
- MR-PRESSO
- leave-one-out analysis
- Steiger Direction test
- Reverse analysis

Sensitivity analysis
- Cochran’s Q test
- MR-Egger regression test
- MR-PRESSO
- leave-one-out analysis
- Steiger Direction test
- Reverse analysis
<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Exposures</th>
<th>Panel</th>
<th>IVs</th>
<th>Estimate</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADHD</td>
<td>HLA DR on CD33dim HLA DR+ CD11b+</td>
<td>Myeloid cell</td>
<td>12</td>
<td>1.027 (1.019 – 1.035)</td>
<td>6.15E–08</td>
</tr>
<tr>
<td></td>
<td>CD33 on CD33dim HLA DR+ CD11b−</td>
<td>Myeloid cell</td>
<td>13</td>
<td>1.017 (1.008 – 1.026)</td>
<td>3.33E–02</td>
</tr>
<tr>
<td></td>
<td>CD33 on HLA DR+ CD11b−</td>
<td>Myeloid cell</td>
<td>10</td>
<td>1.026 (1.012 – 1.040)</td>
<td>3.33E–02</td>
</tr>
<tr>
<td></td>
<td>CD33 on basophil</td>
<td>Myeloid cell</td>
<td>5</td>
<td>0.965 (0.951 – 0.980)</td>
<td>1.48E–03</td>
</tr>
<tr>
<td></td>
<td>FSC–A on lymphocyte</td>
<td>TBNK</td>
<td>7</td>
<td>0.947 (0.919 – 0.975)</td>
<td>3.33E–02</td>
</tr>
<tr>
<td></td>
<td>Mo MDSC AC</td>
<td>Myeloid cell</td>
<td>9</td>
<td>1.049 (1.022 – 1.077)</td>
<td>3.50E–02</td>
</tr>
<tr>
<td></td>
<td>CD33 on CD33dim HLA DR−</td>
<td>Myeloid cell</td>
<td>11</td>
<td>1.025 (1.011 – 1.039)</td>
<td>4.70E–02</td>
</tr>
<tr>
<td>MDD</td>
<td>CD4 on resting Treg</td>
<td>Treg</td>
<td>7</td>
<td>0.972 (0.962 – 0.982)</td>
<td>2.65E–05</td>
</tr>
<tr>
<td>PTSD</td>
<td>CD11c on granulocyte</td>
<td>cDC</td>
<td>14</td>
<td>0.919 (0.884 – 0.954)</td>
<td>5.38E–03</td>
</tr>
<tr>
<td></td>
<td>CD25++ CD8br %T cell</td>
<td>Treg</td>
<td>10</td>
<td>1.080 (1.042 – 1.119)</td>
<td>5.38E–03</td>
</tr>
<tr>
<td></td>
<td>HVEM on EM CD8br</td>
<td>Maturation stages of T cell</td>
<td>7</td>
<td>1.050 (1.026 – 1.074)</td>
<td>5.38E–03</td>
</tr>
<tr>
<td></td>
<td>IgD– CD24– %B cell</td>
<td>B cell</td>
<td>12</td>
<td>1.040 (1.021 – 1.059)</td>
<td>5.38E–03</td>
</tr>
<tr>
<td></td>
<td>SSC–A on myeloid DC</td>
<td>cDC</td>
<td>10</td>
<td>1.063 (1.031 – 1.096)</td>
<td>1.37E–02</td>
</tr>
<tr>
<td></td>
<td>Basophil %CD33dim HLA DR− CD66b–</td>
<td>Myeloid cell</td>
<td>12</td>
<td>1.061 (1.029 – 1.094)</td>
<td>1.68E–02</td>
</tr>
<tr>
<td></td>
<td>IgD on IgD+ CD38br</td>
<td>B cell</td>
<td>15</td>
<td>1.055 (1.024 – 1.086)</td>
<td>3.73E–02</td>
</tr>
<tr>
<td></td>
<td>CD25 on IgD+ CD24–</td>
<td>B cell</td>
<td>17</td>
<td>0.964 (0.944 – 0.984)</td>
<td>4.74E–02</td>
</tr>
<tr>
<td>SCZ</td>
<td>CD11c+ monocyte %monocyte</td>
<td>cDC</td>
<td>11</td>
<td>1.087 (1.035 – 1.120)</td>
<td>6.45E–05</td>
</tr>
<tr>
<td></td>
<td>CD64 on CD14+ CD16+ monocyte</td>
<td>Monocyte</td>
<td>7</td>
<td>0.939 (0.913 – 0.965)</td>
<td>1.40E–03</td>
</tr>
<tr>
<td></td>
<td>CD28– DN (CD4–CD8–) %T cell</td>
<td>Treg</td>
<td>14</td>
<td>0.962 (0.946 – 0.985)</td>
<td>1.40E–03</td>
</tr>
<tr>
<td></td>
<td>HLA DR+ CD8br %T cell</td>
<td>TBNK</td>
<td>23</td>
<td>1.041 (1.020 – 1.062)</td>
<td>2.30E–02</td>
</tr>
<tr>
<td></td>
<td>CD38 on transitional</td>
<td>B cell</td>
<td>16</td>
<td>0.951 (0.926 – 0.976)</td>
<td>2.88E–02</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Exposures</th>
<th>Family</th>
<th>IVs</th>
<th>Estimate</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADHD</td>
<td>S. parasanguinis</td>
<td>Streptococcaceae</td>
<td>3</td>
<td>0.964 (0.946 – 0.982)</td>
<td>1.68E–02</td>
</tr>
<tr>
<td></td>
<td>A. indistinctus</td>
<td>Rikenellaceae</td>
<td>10</td>
<td>0.948 (0.920 – 0.976)</td>
<td>2.07E–02</td>
</tr>
<tr>
<td></td>
<td>R. bromii</td>
<td>Ruminococcaceae</td>
<td>6</td>
<td>1.110 (1.048 – 1.175)</td>
<td>2.07E–02</td>
</tr>
<tr>
<td></td>
<td>B. massiliensis</td>
<td>Bacteroidaceae</td>
<td>4</td>
<td>1.074 (1.032 – 1.118)</td>
<td>2.07E–02</td>
</tr>
<tr>
<td>family</td>
<td>Clostridiales noname</td>
<td>Clostridiales_noname</td>
<td>7</td>
<td>1.102 (1.042 – 1.165)</td>
<td>2.36E–02</td>
</tr>
<tr>
<td></td>
<td>R. callidus</td>
<td>Ruminococcaceae</td>
<td>5</td>
<td>1.063 (1.026 – 1.101)</td>
<td>2.36E–02</td>
</tr>
<tr>
<td>PTSD</td>
<td>S. parasanguinis</td>
<td>Streptococcaceae</td>
<td>3</td>
<td>0.904 (0.880 – 0.929)</td>
<td>8.38E–11</td>
</tr>
<tr>
<td>SCZ</td>
<td>R. callidus</td>
<td>Ruminococcaceae</td>
<td>5</td>
<td>1.040 (1.024 – 1.055)</td>
<td>1.21E–04</td>
</tr>
<tr>
<td></td>
<td>family Ruminococcaceae</td>
<td>Ruminococcaceae</td>
<td>6</td>
<td>0.879 (0.832 – 0.928)</td>
<td>3.78E–04</td>
</tr>
<tr>
<td>TS</td>
<td>S. thermophilus</td>
<td>Streptococcaceae</td>
<td>4</td>
<td>1.123 (1.070 – 1.178)</td>
<td>2.24E–04</td>
</tr>
<tr>
<td></td>
<td>genus Barnesiella</td>
<td>Porphyromonadaceae</td>
<td>13</td>
<td>0.829 (0.761 – 0.902)</td>
<td>1.05E–03</td>
</tr>
<tr>
<td></td>
<td>genus Ruminococcaceae noname</td>
<td>Ruminococcaceae</td>
<td>8</td>
<td>1.175 (1.083 – 1.276)</td>
<td>5.63E–03</td>
</tr>
<tr>
<td></td>
<td>genus Odoribacter</td>
<td>Porphyromonadaceae</td>
<td>8</td>
<td>1.440 (1.186 – 1.750)</td>
<td>9.48E–03</td>
</tr>
<tr>
<td></td>
<td>R. bacterium D16</td>
<td>Ruminococcaceae</td>
<td>7</td>
<td>1.169 (1.064 – 1.285)</td>
<td>3.79E–02</td>
</tr>
</tbody>
</table>